Combined immune checkpoint inhibitors, immunotherapy with picibanil-based intraperitoneal imiquimod, and chemotherapy in cases of advanced cervical cancer and failure of concurrent chemoradiation therapy: A new clinical paradigm-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combined immune checkpoint inhibitors, immunotherapy with picibanil-based intraperitoneal imiquimod, and chemotherapy in cases of advanced cervical cancer and failure of concurrent chemoradiation therapy: A new clinical paradigm

Published:2022 Issue:4 Volume:9 Page:165
ISSN:2311-3006
Container-title:Journal of Cancer Research and Practice
language:en
Short-container-title:J Cancer Res Pract

Author:

Lin Cheng-Tao,Peng Hsiu-Huei,Soong Yung-Kwei,Wu Chiao-En

Publisher

Medknow

Subject

Cancer Research,Oncology

Reference8 articles.

1. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: Results from the Phase I/II CheckMate 358 Trial;Naumann;J Clin Oncol,2019

2. Updates in systemic treatment for metastatic cervical cancer;Chao;Curr Treat Options Oncol,2014

3. Immunotherapy for advanced or relapsed cervical cancer;Lin;Gynecol Minim Invasive Ther,2013

4. UpToDate, Ipilimumab: Drug Information. Available from: https://www.uptodate.com/contents/table-of-contents/drug-information. [Last retrieved on 2020 Mar 05].

5. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer;McDermott;Drugs Today (Barc),2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP